CCA
LAB icon

Cruiser Capital Advisors’s Standard BioTools LAB Stock Holding History

Cruiser Capital Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$165K – 83
2021
Q3 		$165K Hold
25,000
– – 0.14% 46
2021
Q2 		$154K Buy
+25,000
New +$134K 0.13% 47

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cruiser Capital Advisors's LAB Position: Q4 2021 in Review

Cruiser Capital Advisors sold out of Standard BioTools (LAB) in Q4 2021, closing a stake of 25,000 shares — an estimated $165K sold.

Cruiser Capital Advisors first reported a position in LAB in Q2 2021 and held it in 2 quarters. The position peaked at $165K in Q3 2021. 121 funds tracked by Wall St. Rank hold LAB as of Q4 2021.

  • Cruiser Capital Advisors reported no remaining Standard BioTools position as of Q4 2021 after selling out during the quarter.
  • Cruiser Capital Advisors sold 25,000 Standard BioTools shares in Q4 2021, an estimated $165K.
  • Cruiser Capital Advisors first reported a position in Standard BioTools in Q2 2021 and held it in 2 quarters.
  • Cruiser Capital Advisors's Standard BioTools position peaked at $165K in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2021.

Based on Cruiser Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.